BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

Group 1 - BioMarin has made its second acquisition in 2025 as part of its strategy to diversify its product portfolio [1] - The company is responding to the commercial failure of a hemophilia A gene therapy [1]